A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 683 participants.
Also called NCT05259033
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 683 participants
- Sponsor
- Registry
-
NCT05259033
-
- Other papers using this trial's data
- Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Brazil, Canada, China, France, Greece, Hungary, Israel, Japan, Russia, Slovakia, Sweden, Switzerland, Taiwan, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT05259033. Randomized; no masking; primary purpose treatment. Start 2022-04-11 (actual); primary completion 2023-12-13 (actual). Results posted on 2025-01-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)
- Acronym
- COMBINE 2
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- IcoSema
- Intervention (Drug)
- Semaglutide 1 mg
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct05259033- Content hash
4792686b9341735842ab23e333b86ad4edfbb40e8b8f861c06cff604397bbc51